Research Article

Association between Glucocorticoids and Mortality in Patients with Severe Pneumonia: A Systematic Review and Meta-Analysis Based on Randomized Controlled Trials

Table 1

Characteristics of 12 included literatures.

AuthorStudy designLocationSettingIntervention/placeboCorticosteroids usedMortality outcome (12)Length of hospital stay (d) (7)Length of ICU stay (d) (7)ARDS incidenceNosocomial infection (6)Mechanical ventilation required (d) () (10, 4)

Tongyoo et al. [14]RCTThailandIn hospital98/9950 mg hydrocortisone intravenously every 6 h daily/normal saline on the same time schedule22/27
RR 0.82 (0.5-1.34)
NANA22/2717/19
33/21
Ceccato et al. [24]Post hoc analysis of RCTSpainICU56/50Methylprednisolone2/1
HR 0.72 (0.11-5.44)
NANA6/5
Nafae et al. [16]Open-label RCTEgyptICU60/20Hydrocortisone4/6NANA8/5
Torres et al. [13]Double-blinded RCTSpainIn hospital55/57Methylprednisolone6/911 (7.5-14)/
10.5 (8-15)
5 (3-8)/6 (4-8)
NANA5/10
Wittermans et al. [21]Double-blinded RCTNetherlandsIn hospital203/198Dexamethasone4/74.5 (4-5)/5.0 (4.6–5.4)
NANANANA
Fernández-Serrano et al. [15]Double-blinded RCTSpainIn hospital28/28Methylprednisolone0/110 (9-13)/12 (9-18)
6.5 (5.5-9)/10.5 (6.25-24.5)
1/2NA1/5
Moreno et al. [17]Propensity score matching study of RCTSpainICU604/1242Methylprednisolone, prednisolone, or dexamethasone166/234NA10 (5–19)/8 (5–18)
NA139/248506/921
Li et al. [18]RCTChinaIn hospital1055/1086Hydrocortisone, methylprednisolone, or dexamethasone261/76NANANA227/154367/49
Lee et al. [19]RCTSingaporeIn hospital612/2037Hydrocortisone, methylprednisolone, or dexamethasone70/33
HR 1.7 (1.1-2.6)
NANANANANA
Kim et al. [20]Open-label RCTKoreaICU107/138Methylprednisolone or dexamethasone62/3766/7061/3091/71
Cao et al. [22]Open-label RCTChinaIn hospital65/65Hydrocortisone, methylprednisolone, or dexamethasone27/10NANANA17/1838/27
Brun-Buisson et al. [23]Open-label RCTFranceICU83/125Hydrocortisone, methylprednisolone, or hydrocortisone28/2123.2 (12.2-28.8)/18.1 (12.1-29.8)22 (13–39)/17 (11–30)NA38/4476/56
10.2 (9.8-16.8)/14.4 (13.2-23.3)